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Patient views about the impact of ulcerative
colitis and its management with drug
treatment and surgery: a nested qualitative
study within the CONSTRUCT trial
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Abstract
Background: A nested qualitative interview study within the CONSTRUCT trial was conducted to explore
experiences and perceptions of patients with acute severe ulcerative colitis following treatment with infliximab
or ciclosporin, surgery, or other medication.
Methods: Two hundred seventy patients with steroid-resistant ulcerative colitis were randomised to either
infliximab or ciclosporin. Interviews were conducted with 20 trial participants. Thirty-five data capture events took
place in total, 20 interviews conducted 3 months after treatment and a further 15 interviews with the same cohort
as second interviews at 12 months.
Results: Disease duration varied but similar stories emerged about how people adjusted to living with ulcerative
colitis. Issues raised by patients included; the debilitating effect of the disease on quality of life, living with the
unpredictability of symptoms and treatment, dealing with embarrassment and stigma and the desire to share
knowledge of the disease with others to combat the private nature of this debilitating illness and bring greater
visibility to patient experience of symptoms and outcomes.
Conclusion: Patients were more positive about treatment with infliximab than ciclosporin, mainly due to the
cumbersome intravenous regimen required for ciclosporin. Prompt diagnosis is required and early reporting of
changes in symptoms is encouraged to ensure appropriate treatment.
Trial registration: This trial is registered with the ISRCTN registry; number ISRCTN22663589. The date of registration
was 16/05/2008.
Keywords: Qualitative research, Patient, Ulcerative colitis, Ciclosporin, Infliximab, Surgery
Background
Ulcerative colitis (UC) is a chronic debilitating disease
that affects ~ 150,000 people in the UK [1, 2]. There
are many unanswered questions regarding the causes
and course of the disease, its treatment, management,
and outcome; despite a background of rapidly devel-
oping new therapies. Patients with acute severe colitis
will require hospital admission. Treatment includes
intravenous steroids but about 40% of patients are
resistant to this [3, 4]. In the past, when no other
treatment was available, emergency colectomy was the
only option. Although mortality following emergency
colectomy has fallen over time, 10% of patients die
within 3 months of surgery [5]. Infliximab and ciclos-
porin are immunosuppressive drugs that offer hope
for the treatment of steroid resistant UC, with evi-
dence that they are both effective in the short term [6,
7], particularly among patients who respond partially
to steroid treatment.
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This article describes a qualitative study undertaken as
part of a trial: Comparison Of iNfliximab and ciclosporin
in STeroid Resistant Ulcerative Colitis: a Trial (CON-
STRUCT), a UK-wide pragmatic randomised controlled
trial (RCT) comparing the clinical and cost effectiveness
of infliximab and ciclosporin for patients with steroid
resistant UC, using quantitative, qualitative, health eco-
nomic and data-linkage research methods [8–10]. This
article adheres to CONSORT guidelines for reporting
parallel group randomised trials [11] where the informa-
tion is pertinent to the qualitative study being presented.
The CONSTRUCT trial as a whole has been reported with
adherence to CONSORT guidelines elsewhere [8, 9].
CONSTRUCT’s primary outcome measure was pa-
tients’ quality of life and the trial showed no significant
differences between the two treatments in this measure
of clinical effectiveness [8]. The qualitative element of
the study contributed to the trial’s specific objectives of
comparing quality of life across the two treatment
groups from the patient perspective, investigating partic-
ipants’ views about the two treatments, experiences of
the drug regimens and opinions about how easy each
drug was to handle, including perceptions of side effects
and ongoing quality of life. The main aim of the qualitative
study was to investigate patients’ priorities for their health
and wellbeing, views of different drug treatment and sur-
gery, and opinion regarding how well they responded to
treatment.
Whilst studies have acknowledged specific character-
istics of UC such as fatigue [12–15]; unpredictability
[16, 17]; stigma [18] and surgical treatment [19, 20], to
the best of the authors’ knowledge, no studies, qualita-
tive or otherwise, have reported, in depth and across a
wide UK-based patient cohort on adult patient experience
of UC in relation to infliximab, ciclosporin, or surgical
intervention. However, qualitative studies have consid-
ered: patient experience in relation to non-medical adap-
tation and non-medical intervention [21], disease burden
[22], and a full review has been undertaken of generic
meanings around living with inflammatory disease [23]. In
addition, some qualitative studies have been undertaken
relating to adolescent experience and those transitioning
to early adulthood [24, 25], such as a study of adolescent
hospitalization, and paediatric-provider relationships, as
patients transition out of care settings. This gap is some-
what surprising given that qualitative methods are well
suited to investigating personal experience in relation to
drug taking or surgical intervention [26], and individual
perceptions and belief and meaning systems [27, 28] and
can help to clarify patients’ understanding of their disease
and its treatment.
In order to determine and understand CONSTRUCT
trial participants’ experiences and perceptions of living
with UC and to disclose details of their experiences of
two treatments with or without surgical intervention,
the study team conducted telephone interviews at two
stages in the study: at approximately 3 months, and
again at 12 months after patients received treatment.
This article presents a description of the interviews




Between June 2010 and February 2013, and with ap-
proval from a multicentre research ethics committee,
CONSTRUCT recruited patients from 52 district general
and teaching hospitals in England, Scotland and Wales.
With informed consent, 270 patients, aged 18 and over,
with acute severe UC, who failed to respond to intraven-
ous steroids, were recruited to the trial and randomly
allocated to treatment with infliximab or ciclosporin.
The definition of acute severe ulcerative colitis used was
patients admitted as emergency admissions with severe
colitis [29], a Mayo Score of at least 2 (on endoscopic
finding or clinical judgement) who had failed to respond
to a course of about 2–5 days of intravenous hydrocorti-
sone therapy, who also had either: histological diagnosis
of ulcerative colitis in that episode; histological diagnosis
of indeterminate colitis in that episode when clinical
judgement suggested a diagnosis of ulcerative colitis ra-
ther than Crohn’s disease; symptoms typical of ulcerative
colitis awaiting histology; or history of ulcerative colitis
confirmed histologically. Patients did not choose which
treatment they received or whether they had surgery.
After consenting to participate in the trial they were
randomly allocated to receive infliximab or ciclosporin.
Surgery was one of the predefined outcomes measured
in the trial and was offered as part of patient care if rec-
ommended by the clinical team. At the time of consent
to the trial, participants were asked to consent to be
interviewed at approximately 3 months and again at 12
months post allocation.
For this qualitative study there were no exclusion
criteria. We purposively recruited equal numbers of
participants from the ciclosporin and infliximab groups
who had participated in the original trial and randomly
received either infliximab or ciclosporin (baseline char-
acteristics of the participants can be found in Table 1).
Detailed inclusion and exclusion criteria for the trial and
more extensive detail about all aspects of study design,
data collection, analysis and reporting can be found in
the full study report [9].
As 52 hospitals in the UK took part in CONSTRUCT,
the trial participants were geographically widely dis-
persed, so for participant convenience and confidentiality,
semi-structured interviews [30] were conducted by tele-
phone when the patients were at home. Semi-structured
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interviews are a useful approach if a researcher wishes to
ensure research participants have the time and space to
expand on their answers narratively. Using this approach,
participants were encouraged to explain any nuance or
ambiguity in their initial answers and could expand, safe
in the knowledge that they would not be interrupted.
Using a telephone interview technique ensured wider
data capture and greater reach and scope than would
have been achievable had face-to-face interviews been
attempted. Travel pressures and the accompanying re-
source implications were removed as was the potential
for patients to get embarrassed discussing sensitive topics
with a stranger, face-to-face [31].
Semi-structured interviews enabled the trial qualitative
researcher to guide the interviewees through the ques-
tions whilst giving participants the opportunity to not
only develop their responses but also raise issues that
were important to them. In accordance with the qualita-
tive study aims, the researcher explored participants’
priorities for their health and wellbeing, the ease with
which patients were able to take the drugs and drug ex-
perience including their view of a drug’s side effects, and
their response to treatment including the possibility of
having to undergo surgery following drug treatments.
An interview schedule was developed comprising key
questions aligned to these aims. The opening questions
were designed to encourage participants to think and
talk about their health, what was important to them, and
what good and poor health meant to them. These ques-
tions were followed by more specific questions about
their treatment experiences, drug regimens, management
of drugs and outcomes.
After the interviews commenced, it became apparent
that some of the participants that had required surgery
to treat their UC had had that surgery, between random-
isation and their three-month follow-up and while the
interview schedule was originally designed to examine
overall views of surgical intervention, should it be neces-
sary, the interview schedule was extended to capture the
views of these participants as well.
Table 1 Demographic characteristics of interview participants






Asian or Asian British 2 0
Black or Black British 0 0
Other 0 0
Mixed 0 0
Weight (mean, kg) 72.7 (range 52 to 102) 76.9 (range 53 to 125)
Height (mean, m) 1.68 (range 1.55 to 1.79) 1.71 (range 1.58 to 1.80)
Smoking Status
Non-smoker/ Ex-smoker 6 5
Never smoker 4 5
Smoker 0 0
Truelove & Witt’s score
Severe 9 5
Not severe 1 5




Quality of life scores
EQ 5D 0.38 (range − 0.08 to 0.73) 0.56 (range 0.29 to 0.81)
CCQ-32 (mean) 0.35 (0.13 to 0.56) 0.37 (range 0.24 to 0.49)
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Sample and recruitment
The CONSTRUCT Protocol [10] defined a sample of
10% of the total of 480 randomised participants to be
interviewed. Purposive quota sampling supported the
identification of 12 consenting patients from each arm
of the trial in view of the belief that a total of 24 partici-
pants, interviewed on two occasions (n = 48 data capture
events), would yield a range of views and opinions re-
garding therapy and surgical intervention, as well as a
mix of participants according to age and gender and
patients from a range of centres. The sample size was
supported by the literature’s response to sample size ad-
equacy in qualitative research studies [32] and the need
to ‘represent the voice of the people’, with the aim of
achieving data saturation at this point, or continuing
sampling until data saturation was achieved (where no
new data codes and categories are evident) [33]. As in-
terviews would inherently disclose which trial arm the
participant was in, the interviewers and analysts were
unable to remain blinded. However, this would enable
exploration of experiences of the drugs in depth, to meet
the qualitative study aims and thus was deemed accept-
able. Any potential bias in interpretation would be
addressed by having more than one person analyse the
data and come together as a group for consensus [34].
Analysis
Data were analysed using both thematic and schema ana-
lyses and in accordance with the interview schedule [35].
Thematic analysis is an approach to analysis that implies
both implicit and explicit ideas evident in the data col-
lected, through the coding and classification of data into
meaningful and relevant categories and themes. These cat-
egories and themes, as they are developed and refined, link
the raw data to ‘summary markers’ that indicate the raw
data’s main content and context. As a result, the thematic
analytic framework needs to be both comprehensive and
succinct, encapsulating the main issues arising in the raw
material in an abbreviated fashion that is both accepted
and clear [36]. Schema analysis, on the other hand, con-
centrates on identifying patterns within text which can
provide valuable information about how people work,
behave or communicate, concentrating on these speech
patterns in relation to the original study aims and objec-
tives [37]. Schema analysis presents these patterns as
people’s approach to the use of cognitive simplification. It
examines through speech patterns how people express
their views, opinion and experiences and how they make
sense of complex information to which they are exposed.
Analysis starts with a thorough reading and rereading of
pieces of text, such as interview or focus group transcripts,
followed by the identification of key issues evident as
themes and categories within the text. At the same time
schema analysis looks at the repetitive aspects of patterns
of speech and at the way people introduce metaphor to
present themselves to others [37].
The thematic analysis commenced after four interviews
had been completed and continued iteratively until data
saturation was confirmed to have been reached [33] and
where no new codes or themes were revealed. Due to the
rich and detailed amount of data arising from the inter-
views we also deemed that ‘information power’ was suffi-
cient to meet the study aims and objectives [24]. The
transcripts were distributed to three qualitative researchers,
one of whom was the primary researcher involved in data
capture. Each researcher read the transcripts and consid-
ered the themes that were emerging. The three researchers
then met to discuss their findings and develop an analysis
framework and an iterative process followed with all the
transcripts, whereby themes and concomitant categories
were honed down and clarified amongst all three re-
searchers through consensus agreement.
The wider CONSTRUCT study team was then in-
volved in a schema analysis exercise [38]. This process
was chosen for four reasons: a) to enhance the thematic
analysis framework by verifying that all framework
elements were cogent and comprehensible, b) to be
multidisciplinary, c) to build consensus into the data
assessment process to ensure decision-making and inter-
pretation was rigorous and trustworthy, and c) to give
those involved with the analysis of other study datasets
an insight into the lives of the participant group. Mem-
bers of the study team, a multi-disciplinary group of
gastroenterologists, researchers, statisticians and trialists
were asked to read three participant transcripts, one
from a participant treated with infliximab, one from a
participant treated with ciclosporin and one from a par-
ticipant who had had ciclosporin followed by surgery.
The members involved were then asked to write one-
page schematic overviews of the main features of each of
the three texts, in keeping with participants’ health and
illness stories, and as they related to quality of life and
drug regime issues. These overviews were then reviewed
and integrated into one overview of each interview
which was then discussed and refined in group discus-
sions between team members. Data analysis followed a
similar pathway to the team’s previous, qualitative,
gastroenterology trials data, including secondary assess-
ment by a team of qualitative data analysts of a subset of
all interview transcripts to ensure the thematic template
was rigorous and findings efficacious. As teamwork
continued, combined analyses or all transcript schemas
contributed to a final thematic framework [39].
Results
Number of interviews conducted
Whilst 24 participant interviews were planned, after 20
three-month interviews had been analysed, data saturation
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was reached, with multiple qualitative analyst coming up
with the same themes and no new themes arising, and it
was agreed that no further interviews were needed for the
first stage of data capture. The 20 interviews at 3 months
were split evenly between those randomised to infliximab
and those to ciclosporin, and three in each group had also
had a colectomy. There were three females and seven
males in each treatment group and their ages ranged from
21 to 75 years, as shown in Table 2.
We conducted 35 interviews with 20 participants. The
full cohort were approached for a second interview at
12 months and at this stage only 15 of the interviewees
from the original cohort of 20 agreed to a second inter-
view (eight infliximab, seven ciclosporin patients). The
reduction in numbers resulted from: one participant
having died, two participants not wishing to take part
and our inability to contact two participants. From each
of the two treatment groups, one participant (one male
and one female), had undergone a colectomy, while one
male participant who had undergone a colectomy before
the first interview had since had two further operations
(pouch surgery followed by ileostomy closure).
The length of time since the participants had been di-
agnosed with UC varied from just a few weeks to as long
as 30 years. However, those who had only recently been
diagnosed had generally been experiencing symptoms
for several months. The demographic information for
those patients who agreed to be interviewed was com-
pared to the cohort of patients who were not inter-
viewed and found to be comparable.
With many participants working, the interviews often
took place when people returned home from work. The
interviews lasted 30–45min on average, and all partici-
pants agreed that the interviews could be recorded.
Transcribed interviews were reviewed by the primary
qualitative researcher before being anonymised by using
the participant’s study ID, with all names and geograph-
ical details removed.
Results of the interview analysis
Despite a wide age range amongst participants, and vari-
ation in the duration of their disease, similar stories were
revealed about living and adjusting to UC, the physical,
mental and emotional impact of the condition, the treat-
ments, and people’s concerns and hopes for the future.
The details of the participants’ experiences of UC are
presented in a narrative form to reflect participants’ de-
scriptions of how they ‘journeyed’ through their illness,
and according to their individual storylines, which they
generally presented as: realisation of the problem, receipt
of treatment, management of the condition and views of
what the future held. Presenting the findings in this way
indicates the joined-up story of an illness course experi-
enced as chronic, in terms of how UC becomes present
and begins to take root in people’s lives, as well as
people’s ongoing expectations and the consequences of
the illness in the longer-term.
Similar findings from the interviews at 3 and 12
months are not reported to avoid repetition, but new
views and experiences revealed at the 12-month inter-
views are included. By presenting outcomes in this way,
we have aimed to identify both personal experience of
health and illness, and opinions of care and treatment
options from an individualistic perspective and over a
period of 1 year. Data capture and analysis extended
over the year and was finalised early 2016.
All quotes are from trial participants. Quotations are
presented in italics followed by an anonymised code for
each participant and the line number of the quote from
the transcript.
Participants’ views on their general health
For many of the participants, UC was the only signifi-
cant illness they had experienced, and even for those
with longer term UC, their recent inpatient stay was
often their first admission to hospital with the disease.
Thus, it soon became apparent that many participants
had managed their problems themselves at home, and
had not given much thought to the implications of ill-
health, or needing to enter more formal healthcare facil-
ities. It is against this background that participants
reflected on their desire to continue to lead a ‘normal’
life, to retain the ‘freedoms’ to which they were accus-
tomed, and to have the energy to undertake everyday
activities including socialising, working and travelling,
without constraint. They considered good health as
having plenty of energy, not being reliant on medication,
being symptom- and pain-free and not having to go to
the toilet every few minutes. In contrast, participants re-
lated bad health to being ‘imprisoned’, that is to say,
housebound, unable to socialise and to be burdened with
physical constraints relating to pain, discomfort, lack of
energy and a dependency on others.
These issues were raised on a number of occasions,
especially when participants were asked how their UC
affected their quality of life. Here the intensity of the suf-
fering caused by UC became strongly apparent, particu-
larly for those who had experienced symptoms for only
a few weeks or months: “a bit of a bolt out of the blue”
(GHI0028.164). For this latter group in particular,
Table 2 Details of interview participants
Infliximab Ciclosporin
Males Females Males Females
Number interviewed 7 3 7 3
Age range 23–64 21–44 27–75 31–59
Mean age 44 32 51 43
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admission to hospital was a shock and a frightening ex-
perience, and 3 months after their treatment they were
still adjusting to this life-changing event.
At 12 months, while the course of the disease for the
participants had differed, their basic desire to live a nor-
mal life, to be able to socialise, work and travel, had not
changed.
Onset of illness and diagnosis
A picture emerged of a convoluted and sometimes frus-
trating treatment story from early onset to diagnosis, via
an often-misdiagnosed disease. The story frequently
began with mild symptoms, such as going to the toilet
more often and having some bleeding, which led to an
eventual General Practitioner (GP) visit with a misdiag-
nosis of haemorrhoids: “I wasted about a month going to
see the doctor and he just gave me stuff for piles”
(LMN0009.111). Some participants visited their GP sev-
eral times, but it was only when their symptoms did not
settle and became worse, particularly if weight-loss oc-
curred, that they were referred for an endoscopy. Some
participants who knew they had UC ‘soldiered on’ with
their symptoms, and a couple of participants described
feeling like ‘frauds’ as inpatients amongst some of the
seriously ill people in nearby beds.
A range of issues were raised by participants who dis-
cussed not only their experience of taking drugs, but also
their ability to control symptoms and manage medication
and the impact of medication on symptom control. Some
participants found medication control adapted well to
their changing physical state while others experienced dif-
ficulties in attempting to manage UC. For this latter
group, a range of different medications had been tested
with unpredictable results over time. Of the full cohort,
the participants who fared the best in recognising signs
and symptoms, management of drugs and appreciation of
different treatment options were those who knew they
had UC before their admission. These participants were
cognisant of the fact that as time progressed, treatment
options narrowed to the more powerful drugs or surgery,
which was still seen as the final resort.
Unpredictability of the disease
The unpredictability of the course of the disease was a
problem for many who had no idea when their next
flare-up might occur. A flare-up resulted in pain and dis-
comfort, increased and urgent bowel movements and
bloody diarrhoea, necessitating frequent, rushed visits to
the toilet. Participants described this loss of bodily func-
tion as being unable to rely on their bodies, leading to a
sense of giving up control over their bodies. Life was
planned around access to toilets amid the fear of having
an ‘accident’, and participants jokingly commented on
their knowledge of all the toilet stops on a regular car
journey.
If a flare-up was not controlled, symptoms such as fre-
quent toilet use – maybe 20 to 30 times during the day
and night, had a massive impact on their lives, leading to
severe quality of life deterioration within a matter of
weeks. Participants described how normal life ceased to be
manageable very quickly and how the unpredictability of
the disease had a knock-on effect on their ability or desire
to pursue everyday activities which had previously been a
major part of their lives. When this was the case, all other
activities had to be curtailed, in order for daily lives to be
manageable: “Colitis can make you a prisoner that you
don’t venture far away from a toilet” (DEF0016.60).
At 12 months, all participants continued to be followed
up at hospital and were on medication for UC; six patients
reported no further symptoms, whilst three had experi-
enced flare-ups. They understood that if symptoms devel-
oped, a prompt change in medication could prevent them
becoming as ill as they had been before, and that they
would need to contact their inflammatory bowel disease
(IBD) nurse or GP for advice as they: “would want to catch
it earlier” (BCD0012.214).
Impact of symptoms on the life course
The impact of symptoms like diarrhoea and disturbed
nights resulted in people’s health deteriorating. This re-
sulted in reduced activities, and impacted socialising and
working arrangements, to a state that people found
themselves, in effect, housebound. During these phases,
participants described suffering from a lack of energy,
weight loss and exhaustion, the latter being something
that many people emphasised several times during the
interview: “basically tiredness was one of the things that
was really difficult” NOP0004.91). For many participants,
life had to be put on hold; engendering a significant
change which they found difficult to cope with: “Flare-
up – it was dictating to me what I was able to do, not
me dictating it” (RST0021.15).
Those in employment described how they had tried to
continue working for as long as possible until they
reached a point where it was simply physically impos-
sible for them to carry on. An issue for some younger
UC participants was the potential detrimental effect on
their careers, as a result of ongoing flare-ups requiring
time off work.
The condition could, therefore, be seen to cause huge
changes in lifestyle for those who had to take time off
work, who could not venture out to socialise, and for
those with young children who were unable to care for
them properly.
There appears to be a trajectory for participants of any
age of debilitation, in that they change from someone
with an active lifestyle, to someone for whom the disease
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has an increasingly detrimental effect, which often leads
to a state, that participants describe, in both mental and
emotional terms, as reducing possibilities in their lives.
This effects: going to the toilet, being in great pain and
being bored but unable to do anything to alleviate the
boredom:
“I was spending all day in a chair or in bed barely
able to eat and my life just consisted of going to the
toilet and sitting still trying to occupy my mind and
not go crazy.” (GHI0028.19)
For some patients, UC took them entirely by surprise,
changing them from someone with good health to some-
one with a chronic condition. For many, life took a
different and unexpected path, where their freedom to
travel, pursue hobbies and to work was curtailed or re-
stricted because they could not rely on their body func-
tioning properly. For those wishing to travel, there was
the added difficulty of obtaining travel insurance.
During the 12-month interviews, the quality of life for
participants who managed to bring their symptoms under
control, had improved, with some even able to plan events
with confidence. Participants spoke of the impact of ex-
treme illness, and being diagnosed with a chronic disease,
leading directly to significant life changes, affecting their
jobs, precipitating a house move, or perhaps leading to
self-employment.
Embarrassment about sharing knowledge with others
In contrast to some other chronic conditions, many UC
sufferers considered it to be an embarrassing illness be-
cause of its association with ‘bottoms’, ‘bleeding from
your bottom’, diarrhoea and going to the toilet. As a re-
sult, participants explained that they were selective about
who they shared information about their disease with,
often only discussing it with close family members and
friends, rather than with acquaintances or work col-
leagues. However, when informed, employers and work
colleagues were often found to be understanding and
supportive.
UC is a ‘secret’ disease, difficult to discuss with few
clear and recognisable manifestations. In addition, mani-
festations change rapidly and this unpredictability can
lead to problems in treatment planning and therapeutic
discussion. Participants in this study noted that others
were often unaware of what the experience of UC was
like for them, particularly members of the wider public
implying a lack of a broader awareness of UC as a
chronic condition. Participants, including those who had
had surgery, remarked that a lack of public interest and
awareness was exacerbated by little media interest, few
reviews of the disease, and rare media discussions about
the profile of UC compared to other chronic conditions.
Participants noted that were famous people to come for-
ward more frequently, who had the disease, more media
interest might be engendered. The low profile was at-
tributed to the embarrassing aspects of the disease which
meant it was perceived differently to other chronic
conditions.
At 12 months, similar issues arose, but a participant
reflected: “that you need to be able to speak to people
and share what’s happened to you” (TUV0001.584),
while two surgery participants, in particular, were keen
to share their experiences with other sufferers and help
them understand the impact of surgery and coping with
a stoma.
Impact of UC on family and friends
The life-changing nature of UC clearly impacts on fam-
ilies and friends, particularly during periods of flare up.
Those with young children found themselves unable to
look after and play with their children, while others
found it affected their partner’s social life and could
affect family travel plans:
“ … would like to go around the world with my wife
and we can afford it now but I simply, at the moment
haven’t really got the energy for it” (ABC0010.86).
However, the predominant observation made by par-
ticipants was that the support provided by family and
friends was invaluable, in both practical and emotional
terms. Ensuring others could support them was a posi-
tive outcome, and helped patients to cope mentally, as
the condition became more difficult to manage.
At 12 months, the impact of UC on family and friends
was spoken about by those who had had surgery. A par-
ticipant who visited his workplace to discuss returning
to work was aware that word had got out that he had a
stoma and found some individuals did not look him in
the eye easily but were: “constantly staring to see if they
could see this thing” (DEF0016.680). He found this rude,
and his wife was so annoyed that she had to walk away.
However, one participant felt that friends and family got
bored with the disease so talking to the interviewer was
helpful: “talking to an absolute stranger, vague stranger,
there’s something quite soothing about it … just go
through it from start to finish” (MNO0034.729).
Acquiring knowledge about ulcerative colitis
Participants appeared to be well-informed about their
condition, using the internet to find out more and turn-
ing to support group literature, such as documentation
provided by ‘Crohn’s and Colitis UK’ (a national support
organisation). In addition, many patients were in contact
with an IBD nurse at their local hospital, from whom they
received information and help when their symptoms
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exacerbated. However, participants commented on the lack
of availability of an IBD nurse at all hospitals and were of
the opinion that their support would be invaluable, and
their role should be introduced more thoroughly.
Despite information available, participants had a num-
ber of unanswered questions surrounding the cause of
their UC. They spoke about the possible genetic links to
their disease and mentioned the need for more research
in the area, in order to ensure that other family mem-
bers could be supported if they did get UC or could be
prevented from suffering with the disease. Participants
were also unsure about what triggered a flare–up and
wanted more information on this particular aspect of
their disease, including information about the links
between UC, stress and diet. Ultimately, participants
wanted to see a cure for the condition; and whilst recog-
nising that it might be too late for them, they wished to
support others from having to suffer with the disease.
Participants appeared to be less questioning about UC
at 12 months, as only a few comments arose about the
cause and cure. However, the suggestion that they had
easy access to care appeared to be more important to
them at this point in their disease.
Shared treatment decisions
Participants were well-informed about their UC, knew
the signs and symptoms that indicated a flare-up and
the various treatments available to them, and with this
knowledge, they saw themselves as taking part in shared
decision-making about their treatment with clinicians.
This was particularly evident with regards to surgery as
an option, when participants clearly understood that
they had failed to respond to the medical treatments:
“ … spoke long and hard to the surgeon and medical
doctors and we all agreed that my quality of life would
be improved if the bowel was gone” (DEF0016.362)
Participants clearly understood that if they failed to re-
spond to the various treatments, there could be a time
when their body would make a treatment decision for,
them rather than the decision being made by them or
their clinician: “if you are so bad and it gets to the point
where it could put your life at risk then obviously you
have to have it done” (JKL0033.521).
Comparison of infliximab and ciclosporin from the
participant perspective
All the participants except one had only ever experienced
one of the drugs, (ciclosporin or infliximab) and were ex-
tremely ill when the treatment was first administered. As
a consequence, whichever drug led to a participant’s
health improving, was viewed positively, particularly if it
meant that surgery could be avoided.
Ciclosporin
Participants found being hooked up to a drip continuously
for several days at a time was problematic, in that it was
restrictive: “… loss of freedom, I found that quite irritating,
personally found that frustrating” (BCD0012.218). It also
meant being woken up at night for infusion bag-changes
which caused anxiety, especially when a bag-change was
delayed. Some found the infusion easier than the oral form
of ciclosporin, as blood tests were required to monitor
ciclosporin levels, tablets were large and had a distinctive
smell, and participants had to remember to take tablets
and have them with them when they went away. However,
tablets meant ‘no needles’ and could be taken at home.
There were a number of side effects directly linked to
ciclosporin, including mood swings, rashes on arms, tin-
gling in fingers and toes, increased facial and body hair,
tiredness, hand tremors and cramps in the hands and
feet. Women in particular worried about facial hair dur-
ing the period in which they took ciclosporin.
Two participants did not respond to intravenous
ciclosporin and required emergency surgery. A third
participant initially responded but relapsed and was
given infliximab (the only participant to have experience
of receiving both treatments). In the short term, those
who did respond commented that they had avoided sur-
gery, it got their condition under control and that they
felt much better. At 3 months, participants found it diffi-
cult to comment on the impact of ciclosporin on their
current health as most were no longer taking it and were
on other medications.
Infliximab
Participants found the short intravenous infusion easy: “I
was just lying in a hospital bed so I could doze off, read
a book” (KLM0010.153). They had the same opinion
about further treatments that could be provided to them
as an outpatient - appreciating the shorter time the
treatment took and not having to take tablets: “there is
not any managing of it because it’s a two-hour infusion
and then you’re not due back in for another six to eight
weeks so in that way it’s fantastic” (OPQ0005.395).
The side effects of infliximab were more immediate,
such as a ‘weird’ sensation in the legs, feeling vague and
‘dopey’ and becoming very hot during the infusion, and
one participant described getting hot at night for two to
3 weeks following infusion.
Three participants did not respond to infliximab and
required surgery. A participant who was switched to
infliximab noticed a positive difference in her condition
within a day. In the short term, those who responded
well had positive comments to make, as the treatment
meant they avoided surgery. They noticed a rapid differ-
ence in their state of health and viewed infliximab as a
‘miracle drug’ (GHT0034.331). Again, it was difficult for
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participants to comment on whether they felt the inflixi-
mab was still having an effect at 3 months as they were
taking other medications. A couple of participants felt
the effects were still lasting and two participants felt the
effects wore off as they neared the time of their next
infusion.
By the time of the second interview, none of the par-
ticipants were receiving ciclosporin or infliximab. One
participant from each group had experienced a flare-up
whilst four infliximab and two ciclosporin participants
had no further symptoms since completing the trial
treatment.
At 12 months the majority of the participants spoke
more about other treatments they had received since the
trial treatment, but two recalled that ciclosporin had
been a successful treatment. Three commented on the
convenience of infliximab and that they would be happy
to have it again, whilst one stated that treatment with
infliximab: “every so often would have been easy-peasy”
(QRS028.342) when compared with having surgery and
living with a stoma. One participant explained that be-
cause of funding restrictions, her local primary care trust
would not allow her to continue treatment with inflixi-
mab and she felt her: “quality of life would be much
better now if I was able to continue it” (MNO0034.780).
Surgery
Surgery was considered a final option by most partici-
pants who took part in the interview study, who de-
scribed surgery in terms of the fear and anxiety it raised
in them. They used a range of terms to describe their
worries, terminology that was particularly indicative of a
sense of loss of a body part, such as ‘losing’ a colon. Par-
ticipants were particularly nervous about the outcome of
surgery and the possibility of having to wear a colostomy
bag weighed heavily on their minds, as the following
quotation indicates from one patient who was extremely
concerned before their operation at the thought of hav-
ing to get used to a colostomy bag, post-operations but
whose fears were allayed when they ended up not need-
ing one: “… I walked out of there without a bag … it’s
just the fear of the unknown [having to manage with a
colostomy bag], the effect it can have on your life I sup-
pose, life changes” (TUV0001.242).
Nevertheless, for those who went through with surgery
the end result was commonly unexpectedly positive, and
most participants, in weighing up the consequences of
surgical intervention, retained an open mind to the pos-
sibility of this being an ultimate outcome of their disease
progression were drug or therapeutic intervention to fail.
Those who were told that they would need to have
surgery often described becoming resigned to the inevit-
ability of the operation, accepting the next steps in their
treatment: “I felt really fed up so I was actually quite
happy, to be honest to have the operation by the time it
came round … it wasn’t really a difficult decision to
make in the end” (GHI0028.207).
Surgery participants would have wanted to continue
with medical treatment, but after surgery had taken
place they expressed relief that it had been done, as it
meant an end to their UC: “… the moment I woke up
after the operation I thought, ‘cor this is fantastic’ … the
fog had cleared” (STU0008.188). However, one partici-
pant had fought against surgery when diagnosed 55 years
before, and was relieved that he had not had the surgery
as a young man, whilst another described feeling suicidal
after surgery. Most participants viewed surgery as having
been a good decision but stressed that it did create is-
sues in relation to the practicalities of managing the
stoma and the bag, restricting them to certain types of
clothing and causing concern about how others would
react to seeing the bag, thus curtailing activities such as
swimming: “I’ve got to keep my T-shirt on which is some-
thing I wouldn’t look forward to because I like to jump in
the sea … I don’t want people staring at me all the time”
(STU0008.155). Participants conveyed the point that be-
ing older made it a little easier to cope with the out-
comes of surgery: “… I think when you’re a bit older it is
a lot easier to deal with, mentally really” (QRS0028.307).
Some participants were selective about whom they
told about surgery, because they felt people would not
understand. They tended to tell family and close friends,
and where necessary, work colleagues, and they generally
found that people were supportive. However, some
participants were clearly very conscious of the physical
changes to their body and the impact on personal rela-
tionships, whilst partners were often said to be under-
standing and supportive.
Several participants spoke about the possibility of
having surgery to restore bowel continuity and closure
of their colectomy and age was shown to influence atti-
tudes, with younger participants keen to get on with the
process of getting life back to normal and older partici-
pants appearing more likely to accept life with the
stoma: “If I was, don’t know, 20 years younger, I’d prob-
ably go for reversal because I wouldn’t want to live with
the bag” (QRS0028.289).
At the 12-month interview point participants who
had had a colectomy remarked on strong ongoing per-
sonal relationships and little detrimental effect as a re-
sult of surgery. One participant, who had had surgery
during his first admission, had gone on to have two
further operations to achieve reversal following which
he noted improved quality of life and felt no regrets.
Two men had found that intimate relationships had
suffered but these were an exception to the rule. In-
deed, at 12 months many surgical patients considered
surgery as a cure.
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Concerns, hopes and aspirations for the future
Participants who were yet to have surgery were worried
about where their disease course might take them and
what future treatment might hold for them. Recently
diagnosed patients took time in their adjustment to the
disease especially if they did not yet have corresponding
signs and symptoms that led them to feel unwell or
mentally vulnerable. The disease often precipitated a
gradual physical and mental decline and consequently
participants found it hard to perceive of a time when
their bowel habits would deteriorate still further, and
where the need for medication would be more pressing
Nevertheless even for those people whose symptoms had
resolved, taking medication was a constant reminder
that: ‘it might come back’ (BCD0012.520&600). Younger
patients worried about the effects of the disease on long-
term plans, including starting a family or sustaining
relationships.
The 12-month follow-up interviews were a reminder
to patients of how life had changed. Seven of the eight
participants who had not needed surgery were coming
to accept the challenges and limitations imposed by their
illness and seemed more confident in recognising their
treatment needs. They were reassured by ready access to
advice and guidance from all specialist staff, including
IBD nurses, but surgery remained a clear area of uncer-
tainty. Participants had a range of questions still un-
answered about: stoma reversal, impact of surgery on
personal relationships, stoma management and others’
involvement in future care including close others need-
ing to handle their stoma.
Discussion
Given that CONSTRUCT’s primary outcome measure
was patients’ quality of life and the trial showed no sig-
nificant differences between the two treatments in this
measure of clinical effectiveness [8, 9], the results of this
qualitative study assume greater importance, and the
validity of the findings require detailed scrutiny. The
participants’ views about UC and treatment with inflixi-
mab, ciclosporin and surgery are important, unique and
detailed, and were derived from a broad age range, and a
UK-wide cohort of patients in the largest UC trial of its
kind. The interviewees were chosen at random, but
stratified by age, treatment and surgery, and the demo-
graphic and baseline characteristics of the 20 partici-
pants interviewed, 15 of whom were interviewed on two
occasions, were no different from the rest of the partici-
pant population in the study. Applying the criteria of
credibility, transferability, dependability and confirmabil-
ity set out by Guba in assessing the rigour and trust-
worthiness of data [40], we believe we used a rigorous
and valuable qualitative approach. This included check-
ing that the data being collected and the analysis of that
data was shaped by what the participant population was
saying, ascertained by both building the qualitative data-
set iteratively, so that comments made by one partici-
pant could be expanded and enriched by the comments
of others, and by ensuring data analysis included exten-
sive team work and cross comparisons. We have used
this approach across a range of disease-types [39, 41],
and it is dependent on clarification by multiple analysts,
working together, that knowledge and understanding is
agreed, and consensus has been reached.
The data from interviews reported in this article, with
patients at both three and 12 months after being admit-
ted to hospital with UC, highlights the immense physical
and mental strain of the disease on people’s lives. This
closely aligns with the findings of Rubin et al., who in
their 2008 study describe the difficulties patients face in
living with the debilitating disease and the struggles pa-
tients face managing long-term medication-taking [42].
Some aspects of this appear to set the suffering of people
with UC apart from other chronic diseases, as a result of
unpredictable symptoms and the urgency of needing a
toilet. In addition, unique to UC, is the consensus view
that this is an embarrassing disease, and thus difficult to
share with others, along with the stigma associated with
having a bowel problem. Taft et al. have defined UC as a
long-term secret disease, leading to increased psycho-
logical distress and reduced quality of life, going so far
as to describe it as the disease of body stigma as a result
of the uniquely related bodily functions involved [43]. In
this study, this clearly affected participants’ thoughts
about their quality of life, relationships with others,
plans for social and work life, and future aspirations for
disease management.
Unique to this study are detailed views about the use
and handling of two UC drugs, ciclosporin and inflixi-
mab, unlike other publications on patient experience of
UC more generically focused on patient experience
across disease symptoms and treatments [23]. All the
participants bar one had only ever experienced one of
the drugs, (ciclosporin or infliximab) and were extremely
ill when the treatment was first administered. As a con-
sequence, whichever drug the participant received was
viewed positively, particularly if it meant that surgery
could be avoided. However, ciclosporin was reported in
a more negative light than infliximab across the cohort,
particularly in terms of the length of time necessary for
the intravenous infusion, as opposed to those receiving
an infusion with infliximab, which was quick and
straightforward. Participants being treated with ciclos-
porin also commented on the size of the oral medica-
tion, the problems surrounding having to take tablets on
a daily basis, the inconvenience of having to have regular
blood tests, and the long list of side effects linked to tak-
ing ciclosporin. The participants in this study who were
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allocated infliximab liked the fact that they only had to
return every few weeks to clinic for ongoing treatment,
and that they did not have to remember to take tablets
every day. Participants noticed side effects with both
treatments, but those with infliximab tended to be more
immediate, and lasted for a shorter period of time. It is
interesting to note the comments of the only participant
who was able to compare the two treatments who men-
tioned that it was only after taking infliximab that they
really began to feel better. The lack of comparative data
between the two drugs may reflect the fact that in the
UK, infliximab is restricted for use by some funding
agencies (primary healthcare Trusts). This is confirmed
to be the case by Crohn’s and Colitis UK, who in their
online information sheet explain that ‘Infliximab is a
very expensive drug, so hospitals have to apply for fund-
ing before they can use it on a patient and must review
how effective it is from time to time’. [44] Frustration at
this was expressed in the results section of this paper by
one participant (MNO0034.780) who felt that as a result
of such restrictions, she had not been encouraged to
continue her infliximab treatment.
The interviewees included a widely-based constituency
in terms of disease diagnosis and consequent treatment
pathways. There were those who had been diagnosed
with UC many years ago, some of whom had suffered
from the disease before diagnosis for an extended period
of time, whilst others who had been diagnosed during
their recent admission to hospital, had only had a short-
lived experience of extreme symptoms. However, the
severity of symptoms was something all participants had
in common, which for many indicated how quickly
health can deteriorate with UC, even leading to the need
for a hospital admission.
The extent to which UC had impacted on quality of
life for participants was clear because of the emphasis
put on how highly they valued what they called their
‘normal’ life; their ability to work and socialise. Their
normal life was taken away by the physical symptoms
and these combined with being woken at night to use
the toilet, caused severe fatigue, which has also been
noted in other studies [12–15]. These symptoms had a
significant impact on people’s normal life, and as their
quality of life deteriorated and they became socially iso-
lated, this affected their ability to work and made them
feel even more isolated and inadequate.
Whilst studies acknowledge that UC is an unpredict-
able disease [16, 17], before the detailed reports of our
participants, there was little evidence of exactly what this
meant for patients, nor how the use of specific drugs
and longer-term impact of drug-taking influenced views
of UC. However, the interview data in this trial demon-
strated that the issue of unpredictability: exactly when a
flare-up might occur, whether treatment would be
effective and for how long, as well as concern about soil-
ing oneself, was significant and ever-present for people
who had to work around the effects of symptoms when
planning journeys. For others, projecting about the
longer-term experiences of treatment management, and
the physical difficulties of having to abide by long-term
treatments and all they entailed led to despair. For some,
changes of strategy to enable patients to live with the
disease were needed and to counteract some of the most
pressing worries, for example: changes in lifestyle, cur-
tailment of holidays, stopping hobbies and attending
sports events. Interestingly, unpredictability also extended
to the way participants spoke about their treatment and
whether it would work. For some, the need for eventual
surgery was also uncertain and led to additional anxieties
exacerbated by thoughts about outcomes of surgery and
when it might be urgently required.
Although the stigma associated with UC has been de-
scribed before [1] this qualitative study demonstrates
participants’ feelings about the extent of the embarrass-
ment people experience, and highlighted how this is not
something people find they can readily speak about. Taft
et al., in their study of stigma related to inflammatory
bowel disease reported that stigma was a widespread
phenomenon noting that from a patient cohort of 211
patients, 84% reported related stigma impacting quality
of life, self-esteem, adherence to drug regimes, and self-
efficacy [43]. Apart from concerns about accidents, par-
ticipants in our study indicated their extensive worries
about sharing information with family and friends or
work acquaintances. Participants felt that a wider public
understanding of the disease, which could be achieved
via media channels, would alleviate some of the embar-
rassment factor, and help patients discuss the disease in
more detail with others. A media awareness campaign
could serve as an important way of raising awareness
about UC (and Crohn’s disease), informing the general
public of both the disease and about different surgical
interventions and outcomes. The literature indicates that
misunderstandings around UC and public knowledge of
digestive health and related diseases can be traced back
decades. In a 1987 publication by Kreps et al. [45], for
example, a widescale survey of the American public’s
knowledge of gastroenterological disorders and their im-
pact identified an uninformed and misinformed general
public, with little health promotional support, leading to
minimal healthcare prevention strategies and poor self-
management of care.
It was difficult for participants in this study to attri-
bute their condition at three and 12 months to the trial
treatment, as very few were still taking the trial drug
(ciclosporin is not used in the longer term and there are
funding issues with infliximab). However, if the drugs
had been successful it was clear that they got the
Rapport et al. BMC Gastroenterology          (2019) 19:166 Page 11 of 14
participants to the point where other medication could
then maintain their remission.
In total, eight of the interviewees had had a colectomy
and their data added to the evidence [19, 20] about
patients’ experiences of surgery as a necessary and often
essential treatment for UC. This qualitative study dem-
onstrates that before surgery patients feared the un-
known, and surgery was seen as a last resort, and then
only when everything else had failed to save their colon
was surgery a possibility. However, most patients were
pleased with the results of surgery, and some expressed
regret that it had not been carried out earlier. The un-
predictability of UC has been emphasised in this study
and for many having surgery suddenly removes the
unpredictability of symptoms and medical treatment.
However, after 12 months, difficulties of living with a
stoma came to the fore for some people, leading to a
deterioration in quality of life if the operation could not
be reversed.
Strengths and limitations
The results of this qualitative interview study demon-
strate the importance of incorporating qualitative data
within a clinical trial as this rich data clearly comple-
ments the study’s overall aims and objectives. In a clin-
ical trial showing no significant difference in clinical
effectiveness between the two drugs infliximab and
ciclosporin, understanding patients’ views about their
disease and its treatment becomes more important as
patient views help inform disease management. The data
collected in this study provides an in-depth view from a
patient perspective, of the reality of living and adjusting
to the disease, the degree to which the disease impacts
on people’s lives, and the effects of treatment.
The study has its limitations, however; whilst qualita-
tive research does not seek population representative-
ness, or provide generalisable findings, the number of
interviews could be considered a study limitation and we
cannot make claims for the whole of the UC patient
population in the UK, in particular with regard to pa-
tient views about surgery as a treatment for UC. More
research needs to be conducted to explore the views of
UC patients, post-surgery, postulating to a global
populous and in order to provide more information to
aid the decision-making process of those facing surgery.
As the views of participants following surgery was gener-
ally positive, there should be further research into the
surgical treatment of UC as a real alternative to medical
treatment.
Conclusion
To conclude, this article is the first to report a qualitative
study comparing infliximab and ciclosporin in relation to
patient experience and the treatment of UC, from a
patient perspective, and showing how patients treated
with infliximab generally had a more positive outlook on
treatment than those treated with ciclosporin.
The qualitative study covered a wide range of do-
mains regarding the patient journey, confirming the de-
gree, type and severity of the physical symptoms that
patients with UC experience, particularly when suffer-
ing a flare-up, and illustrating some of the ways that
people learned to live with the disease. However, im-
portantly, these data show the wider effects of these
symptoms on patients’ lives and indicate how easily
people can become socially isolated and stigmatized as
their health deteriorates and symptoms become more
extreme. Consequently, we conclude that greater efforts
should be made to ensure prompt diagnosis, to encour-
age known UC patients to report changes in their
symptoms, and for appropriate treatment to be given as
quickly as possible, sensitive to the needs of patients
and the possibility that not only symptoms, but also
personal experiences can rapidly change.
A significant issue that emerged was that UC and its
treatment remain a significant burden on patients’ lives
because of its unpredictability and lack of knowledge
surrounding the disease and we recommend that better
support and greater information should be considered a
priority, to enable patients to manage the impact of their
symptoms and ongoing treatment regimes, more effect-
ively. Greater information should also be available for
the general public and a new, and concerted effort made
to improve healthcare promotion strategies to increase
disease-knowledge.
Surgery has been shown as a positive option for many
patients. In light of this, further research is needed in-
vestigating the implications of surgical treatment of UC,
as a real alternative to medical treatment, in line with
patients’ views, post-surgery, to support the decision-
making process of those facing surgery.
Finally, an awareness raising campaign about UC (and
Crohn’s disease), including details about surgery, would
encourage people to seek help earlier and help to destig-
matise UC, thereby reducing the embarrassment felt by
sufferers and those living with the outcomes of surgery.
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